Bristol Myers reported positive Phase 3 data for iza-bren
Question
Bristol Myers reported positive Phase 3 data for iza-bren
Direct answer
Positive Phase 3 oncology data supports BMY pipeline value and can move the biotech complex through higher probability of future revenue.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-27
- Published
- 2026-10-27
- Revision
- 1 · 2026-10-27
Cite as: Market Ontology, “Bristol Myers reported positive Phase 3 data for iza-bren”, revision 1, evidence through 2026-10-27. https://marketontology.com/market-events/2026-10-27/bristol-myers-reported-positive-phase-3-data-for-iza-bren-68b19f
How this development reaches the affected companies
| Asset | Exposure and channel | Direction | Evidence |
|---|---|---|---|
| BMY | pipeline value uplift from Phase 3 efficacy data in non-small cell lung cancer | Up1-4w | The Motley Fool says Bristol Myers announced positive Phase 3 trial results and progression-free survival of 11.1 months versus 5.7 months. |
Does this development affect your holdings?
Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related
- 2026-10-27Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLCBMY
- 2026-10-27Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLCBMY
- 2026-10-27Bristol Myers reports positive Phase 3 data on iza-brenBMY
- 2026-10-27Bristol Myers reports positive Phase 3 data on iza-brenBMY JNJ
- 2026-10-27Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLCBMY
- 2026-10-27Bristol Myers Squibb lung cancer candidate doubles progression-free survivalBMY
- 2026-10-27Bristol Myers Squibb lung cancer candidate doubles progression-free survivalBMY XBI
- 2026-10-25Bristol Myers and BioNTech post phase 2 data for pumitamig in NSCLCBMY BNTX
Find trades for this development
Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.
First 10 runs free
See today's live cards
Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.